The ordinary shares and rights that are separated will trade on Nasdaq under the symbols “AFJK” and “AFJKR,” respectively. Those units not separated will continue to trade on Nasdaq under the symbol “AFJKU.” Holders of units will need to have their brokers contact
The units were initially offered by Aimei in an underwritten offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Aimei is a blank check company formed for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Although there is no restriction or limitation on what industry Aimei’s target operates in, Aimei intends to pursue prospective targets that are focused on healthcare innovation. The proceeds of the offering will be used to fund such business combination.
Cautionary Note Concerning Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds from Aimei’s initial public offering and Aimei’s search for an initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Aimei expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aimei’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Aimei Contact:
Chief Executive Officer
+34 678 035200
anatraveneta@hotmail.com
Source: AIMEI HEALTH TECHNOLOGY CO., LTD
2024 GlobeNewswire, Inc., source